2-DAAGSE MASTERCLASS VACCINS
Voor Specialisten en Onderzoekers in de Infectiebestrijding | 1 & 2 oktober 2020 | Almere
Prof. Nils Lycke MD PhD
Professor of Clinical Immunology at the Sahlgrenska University Hospital Gothenburg Sweden.
Professor Nils Lycke is the principal investigator of several internationally recognized
projects focused on Mucosal Immunity and Tolerance where he is a leading researcher in the field.
He has published over 180 original peer-reviewed papers and 35 reviews or book chapters.
Lycke et. al. have pioneered the development of mucosal vaccines with important contributions to the
field in adjuvant construction, including the patented CTA1-DD adjuvant. Basic mechanism of mucosal
immune regulation, vaccine development and clinical assessment of safety & efficacy are other main
research areas. He has been the coordinator of 6 EU-sponsored projects and has received financial
support from EU, NIH, Wellcome Trust, Swedish Cancer foundation, Knut and Alice Wallenberg
Foundation, The Swedish Strategic Research Foundation and the Swedish Research Council, and others.
As a member of the WHO Transdisease Vaccinology Steering Committee for many years, Lycke has been
deeply involved in vaccine design and development as well as interacting with industry and regulatory
authorities. He has been an active contributor to many international and national conferences on the
topic of mucosal immunity and tolerance. He has also organized several international meetings,
including two Keystone symposia, The European Mucosal Immunology Group (he is also founder of
EMIG), The International Mucosal Immunology Congress (SMI). The World Congress of Immunology
(Stockholm), as well as being an invited speaker at congresses of national societies, such as the British,
German, Italian and Irish immunology societies. Prof. Lycke has been a plenary speaker at various
meetings including: EMIG in Prag 2006, ICMI in Tokyo 2007, EMIG in Milan 2008, Nobel forum on IBD
2008, European Immunology Congress Glasgow 2008, Berzelius Conference in Stockholm 2008, ICMI in
Boston 2009, European Immunology Congress Berlin 2009, EMIG in Amsterdam 2010, EFSO Paris 2010,
Adjuvants and Vaccines Dublin 2010, SSI Geilo 2011, ICMI Paris 2011, EFSO Spain 2011 and RIKEN IMS-
RCAI/JSI International Symposium Yokohama, Japan 2013, ICMI in Berlin, Germany, 2016 and Brisbane,
Australia in 2019. IUIS congress in Beijing, China in 2019. He is also an invited lecturer to many
universities, including Scandinavian universities, the NIH and Pasteur Institute (Paris andShanghai/China)
and Imperial College (London).
Dr. Martijn A. Nolte
Principal Investigator at the Laboratory of Molecular Cell Biology Sanquin.
1997 - 2002 PhD at the Free University in Amsterdam
Department: Molecular Cell Biology, VU Medical Center
Promotor: Prof. Dr. Georg Kraal
Copromotor: Dr. Reina Mebius
Title of thesis: Compartments, Cells and Molecules in the Spleen.
2002 - 2004 Postdoctoral fellow at Academic Medical Center, Amsterdam
Department: Hematology / Experimental Immunology
Department head: Prof. Dr. Rien van Oers / Prof. Dr. Rene van Lier
Title research: The Function of CD27 on Hematopoietic Stem Cells.
2004 - 2006 Postdoctoral fellow at Cancer Research UK, London, United Kingdom
Department: Immunobiology Lab
Department head: Dr. Caetano Reis e Sousa
Title research: Dendritic Cells and their Environment.
2006 - 2010 Principal Investigator at Academic Medical Center, Amsterdam
Department: Experimental Immunology
Department head: Prof. Dr. Rene van Lier
Title research: The Influence of the Activated Immune System on
2011 - 2018 Principal Investigator/Head of Laboratory at Sanquin Research, Amsterdam
Lab: Adaptive Immunity Lab
Department head: Dr. Marieke von Lindern
Title research: T cell Immunity and its Impact on Hematopoieis.
2018 - current: Principal Investigator at Sanquin Research, Amsterdam
Lab: Lab of Molecular Cell Biology & Core Facility
Department: Molecular & Cellular Hemostasis
Department head: Prof. Dr. Sander Meijer
Research focus: Microscopy, Adaptive Immunity, Leukocyte migration
Prof. Debby Bogaert, MD, PhD
Chair of Paediatric Medicine, University of Edinburgh
Honorary consultant Royal Hospital for Sick Children
Center for Inflammation Research
The Queen’s Medical Research Institute
47 Little France Crescent
EH16 4TJ, Edinburgh
Prof. dr. Debby Bogaert joined the Centre for Inflammation Research in September 2016. She worked since 2008 as a physician scientist at the Department of Pediatric Immunology of the UMC Utrecht, The Netherlands. There she initiated several ecological studies of the upper respiratory tract microbiome in relation to pathogenesis and prevention of respiratory infections. A Veni and Vidi career grant (NWO) and Top grant (ZonMW) have lead to the validation and adaptation of a metagenomic pipeline for analysis of low-density respiratory microbiota, the set-up of applied bio-informatic methods and the first analyses of environmental effects on such microbiota including mode of delivery, breastfeeding and outcome. Furthermore, she participates in and facilitates microbiological and immunological research projects linked to clinical studies. In the past she worked from 2006 to 2008 as a postdoctoral fellow (Professor M Lipsitch and Professor R Malley, Harvard School of Public Health/Boston Children’s Hospital) where she executed in vitro and animal studies on susceptibility of infants to pneumococcal colonization and infection, with specific emphasis on host-immunity. She obtained her PhD degree cum laude from the Erasmus University in Rotterdam, Netherlands (Supervisors: Professor R de Groot, Professor P Hermans, 1999-2004), for her studies on pathogenesis of pneumococcal infections, focusing on (molecular) epidemiology of bacterial colonization of the upper respiratory tract. Amongst others, she was one of the first to obtain epidemiological evidence for in vivo bacterial interactions occuring at the nasopharyngeal niche.
In parallel, she was also trained as a pediatrician at the Sophia Children's Hospital in Rotterdam, obtaining her license in 2006. She obtained her licence as Paediatric Infectious Diseases and Immunology Specialist at the Wilhelmina Children’s Hospital, Utrecht in 2014.
My research group has a major focus on investigating the physiology and pathophysiology of respiratory infections and inflammation from an ecological perspective, with the ultimate goal to design new or improved treatment and preventive measures for respiratory infections in susceptible populations. To this purpose, the team uses a fully translational approach, combing epidemiological, molecular microbiological, immunological and systems biology approaches to answer their research questions. Moreover, we execute mechanistic studies in vitro and in vivo. She still has a research team in Utrecht, the Netherlands, working on continuation of several birth cohorts and clinical studies.
Dr. Martine I. Bakker
Centrum voor Veiligheid van Stoffen en Producten
Tel. 030-274 3634
After finalizing the studies Chemistry and Environmental Sciences at Utrecht University, Martine Bakker wrote her PhD-thesis at the Research Institute for Toxicology (currently Institute of Risk Assessment Sciences) at the same university. From 2001 she has been working as a scientist and project coordinator at the Research Institute of Public Health and the Environment (RIVM) in Bilthoven. Her area of expertise ranges from modelling of exposure and risk of chemical substances in food and consumer products to management of research data with a focus on nanomaterials.
Dr. Gerben Ferwerda
Internist-researcher, studied medicine at the Faculty of Medicine of the VU University in Amsterdam (cum laude). He then continued his training as a doctor-researcher, a combination of Internal Medicine and PhD research, at the Radboud University Medical Center in Nijmegen. During this period, he also worked at the Sir William Dunn School of Pathology, Oxford University, UK. After completing his doctoral research on 'cross-talk of inflammatory pathways for pathogen recognition', he accepted a full-time position as a senior researcher at the Laboratory of Infectious Diseases (LKI) at the Radboud umc in 2009. At the LKI he leads the research into respiratory viral infections. The main focus of this group is (primary) serious respiratory infections in young children. The aim is to understand the innate immunological mechanisms underlying the development of a serious disease. For this purpose, a regional clinical network has been built and a biobank has been constructed with samples from young children (<12 months) with an acute low respiratory tract infection. Combining transcriptome analysis of leukocytes with functional immunoassays, inflammatory pathways involved in a serious disease course and potential new biomarkers have been identified. This research was conducted within the VIRGO consortium (www.virgo.com). Based on these findings, two research lines are currently underway:
1. The effect of maternal antibodies on the induction of the (innate) immune response during (primary) RSV infections in young children.
2. We are studying this in the context of the development of maternal vaccination.
The role of colonizing bacteria of the respiratory tract (microbiome) in the induction of the innate immune response during acute lower respiratory tract infection and its effect on the severity of the disease. Understanding this mucosal immune response during viral infections is being used to develop new diagnostic and prognostic tests.
Prof. Dr. W. van Eden, MD, PhD
Willem van Eden is an immunologist and medical microbiologist. After his promotion time in Leiden
(promoter Jon J. van Rood), he won two prizes. In 1983 he received a prestigious Bruno Mendel
fellowship from the English Royal Society. This allowed him to conduct research for two years in Israel
(with Irun Cohen) at the renowned Weizmann Institute of Science in Rehovot. In 1984 he was elected
winner of the Prix Zambon Benelux for his work in the field of infectious diseases pathology.
After returning from Israel, he attracted attention due to two simultaneous publications in the top
medical journal Lancet. This prompted de Volkskrant to pay extensive attention to his work on the
possible relationships between infectious and autoimmune diseases.
In 1988 it was discovered by van Eden and colleagues that stress proteins are fundamental for
maintaining self-tolerance. Partly the result of serendipity. The publication in Nature was subsequently
one of the 100 most cited publications in biomedical literature for two years. Building on this finding,
Van Eden and his group are working on a vaccine against chronic inflammatory diseases based on heat
Van Eden is Scientific Director of the university spinn-off company Trajectum Pharma and coordinated
four EU consortia. Van Eden's activities focus on both the veterinary and the human domain.
Until recently he was a member of the health council (committee National Vaccination Program and the
Standing Committee on Infection and Immunity) and is a member of EVAG, the standing committee on
European vaccine policy, of the European Center for Disease Prevention and Control (ECDC).
Rik de Swart studied Biology in Utrecht (completed in 1990) and obtained a
doctorate from Erasmus University Rotterdam in 1995. As a postgraduate researcher he
studied the effectiveness of different candidate measles vaccines in a monkey model.
He now works as an Associate Professor at the Viroscience department of Erasmus MC.
His studies focus on pathogenesis of measles virus, respiratory syncytial virus and human
metapneumovirus, with particular attention to interactions between these viruses and the
immune system of the host. A recurring research theme is immunological identification
correlates of protection or disease: respiratory virus infections often plays an active role in
the disease process. Use is made of this from recombinant viruses expressing fluorescent
reporter proteins, that infected cells both in vitro (in cell culture models) and in vivo
(in animal models) can be demonstrated with high sensitivity. Be with this among others
the main target cells of the measles virus during the onset of the infection, during spread
within the host and upon transmission to the next host identified. In addition, a model was
developed that can explain the measles paradox: the virus induces a strong measles
specific immune response that leads to lifelong protection but ensures simultaneously
for weakening the immune response to other infectious diseases. Rik de Swart 's research
group showed that measles virus is preferentially the infects and depletes memory cells of the
immune system, leading to "Immunological amnesia" (immune amnesia).
Recently supplemental evidence for this model was collected in an observational cohort
study conducted during a measles outbreak among unvaccinated children in the Orthodox
Protestant community. Also by the target cells of the live attenuated measles vaccine virus it was
possible to clarify why measles vaccination does not causes immune suppression.
Rik de Swart was recently involved in overhauling the measles module from the WHO series
"Immunological basis for immunization" (https://www.who.int/immunization/documents/ISBN9789241516655/en/), and at
organizing the exhibition "Vaccination Yes! / No? "At Natural History Museum Rotterdam.
Dr. Rosanne Hertzberger
Rosanne Hertzberger studied Life Science & Technology in Delft and Leiden. She obtained her PhD at the UvA at the Swammerdam Institute for Life Science under the supervision of Joost Teixeira de Mattos and Michiel Kleerebezem on oxygen metabolism of Lactobacillus johnsonii. She did a postdoc at Washington University St Louis School of Medicine in the lab of Dr. Amanda Lewis where she researched glycogen metabolism of vaginal bacteria. She is currently working as a guest researcher on the metabolism of vaginal lactic acid bacteria at VU University Amsterdam in the SysBiolab with Bas Teusink, Frank Bruggeman and Remco Kort.
In addition, she published the book Ode to the E numbers (2017) and Het Grote Niets (2019).
She writes a series on vaccination for De Correspondent and a weekly column in NRC Handelsblad.
Prof. dr. Helen McShane
Director of the Oxford NIHR Biomedical Research Centre; Professor of Vaccinology at Oxford University; Deputy Head (Translation and Personnel), Medical Sciences Division; and an Honorary Consultant Physician in infectious diseases.
Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005 and 2010, she was awarded a Wellcome Senior Clinical Research Fellowship. She currently holds a Wellcome Trust Investigator Award. Helen was elected to be a fellow of the Academy of Medical Sciences in 2019.
Since 2001, Helen has lead a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. She collaborates with several research groups across Africa in TB vaccine clinical trials.
Dr. Ir. Matthijs Jore
Department of Medical Microbiology Radboudumc
6500 HB Nijmegen
Tel: +31 24 3610583
After completing the study of Molecular Sciences (WUR), in the group of Prof. dr. John van der Oost (WUR), PhD research on the CRISPR-Cas system in bacteria that was just discovered at the time and on which he obtained his PhD in 2010. Then, as a postdoc at Oxford University, he investigated how proteins in tick spit inhibit the human complement system. Using protein crystallography, he demonstrated how these proteins bind to human complement proteins, which also led to new insights into complement activation. Since 2016, he has been working as a researcher within the malaria research group at Radboud university medical center. He leads a research team working on the preclinical development of transmission blocking vaccines and antibodies. This includes the discovery of new vaccine candidates and human antibodies, and their in vitro and in vivo validation. He also contributes to the development of a vaccine and therapeutic antibody that will soon be tested in healthy volunteers. In 2019 he received a VIDI grant from NWO to investigate how malaria parasites can escape from the human complement system and how the complement system can be used to make more effective malaria vaccines.
Dr. Ir. Erwin Duizer
Erwin Duizer obtained his master degree in Cell Biology at the Agricultural University Wageningen in 1993 and his PhD after 4 years of research at TNO Food and Nutrition
Research Institute in 1999 at the same university. In 1998 he started a postdoc position at the Research Laboratory for Infectious Diseases, at the national Institute for Public Health and the Environment (RIVM). At the RIVM he worked as senior scientist on viruses and foodsafety and viruses and hygiene while taking on several management tasks in the meantime. In 2015 he became Head of the National Polio Laboratory and WHO Specialized Reference Laboratory for Polio at the RIVM.
1998 –2002 Postdoc: Development of advanced human intestinal epithelial cell cultures for multiplication of enteropathogenic viruses & Molecular detection and viability screening of non-cultivable food borne viruses, Research Laboratory for Infectious Diseases, RIVM, Bilthoven.
2002-2015 Scientist working on “Enteric viruses and Foodsafety”, LIS, RIVM.
2004-2009 Assistant coordinator Food Borne Viruses in Europe (FBVE) network.
2005-2015 Member expert Network “Voedingscentrum”.
Since 2006 Reviewer for several journals including the International Journal of Food Microbiology, Epidemiology and Infection, Journal of Virological Methods, Journal of Clinical Virology and Applied and Environmental Microbiology.
2007-2008 Projectleader gastro-enteric viruses, LIS, RIVM.
2008-2015 Head of section EntericViruses, IDS Virology, RIVM.
Since 2013 board member SKML Virology section.
Since 2015 Head of the National Polio Laboratory and WHO Specialized Laboratory for Polio, RIVM.
Dr. Nathalie Emma MacDermott
2C Westbrook road | London SE3 0NS | +447974818757 | email@example.com
Full GMC registration (6144308) | APLS & NLS certified
Languages: English and German (fluent), French (advanced), Italian (basic), BSL level 1
Nathalie MacDermott is a clinical doctor sub-specialising in paediatric infectious diseases in the NHS. She also has significant experience in medical response to disaster and epidemic situations in Africa and Asia. Nathalie's PhD research (Imperial College London) involved investigating genetic susceptibility to Ebola virus disease in West Africa, including the different phenotypes of disease and the dynamics of disease spread in communities. Her research interests are in paediatric global health, epidemic diseases and susceptibility to infectious disease from the perspective of host genetics.
King’s College London, London UK
Postgraduate medical training – Paediatric infectious diseases subspecialty training
Publications in peer reviewed journals: 5 Citations: 14
Books authored: 1
Imperial College London-University of Makeni Capacity Building 2017-2019
Professor Harish Nair
Harish Nair is Chair of Paediatric Infectious Diseases and Global Health at the Edinburg
Medical School, University of Edinburgh. He is trained in clinical Paediatrics and
Epidemiology. He leads the Respiratory Viral Epidemiology Research Group at the University
of Edinburgh. He has led several large collaborative projects on global child health and
infectious diseases and has raised around £48 million in research grant income and has
published over 100 articles, 27 of them in high impact journals. He currently leads (and is the
coordinator of) the REspiratory Syncytial virus Consortium in EUrope (RESCEU)
(http://resc-eu.org/). He leads the RSV Global Epidemiology Network (RSV GEN) which has
developed the previous and current paediatric global RSV morbidity and mortality estimates.
His current projects include work on child pneumonia, RSV, influenza and other infectious
diseases like pneumococcus, meningococcus and Clostridium difficile. Prof Nair is an
adviser to the World Health Organisation and Bill and Melinda Gates Foundation; and a
founding board member of ResViNET. He is a Fellow of the Royal College of Physicians of
Edinburgh and Faculty of Public Health (UK). He is also the Regional Editor of the Journal of
Global Health and member of several international scientific advisory boards for ongoing
studies on RSV. He was recently awarded the Principal’s Medal for Exceptional Service by the
University of Edinburgh and the Hind Rattan (Jewel of India) award for his contribution to
global public health.
Prof. dr. Jaap T. van Dissel
Jaap van Dissel (1957) is directeur van het Centrum Infectieziektebestrijding (CIb Centrum Infectieziektebestrijding ) van het Rijksinstituut voor Volksgezondheid en Milieu (RIVM Rijksinstituut voor Volksgezondheid en Milieu ). Daarnaast is hij hoogleraar Interne Geneeskunde, in het bijzonder de infectieziekten, bij het Leids Universitair Medisch Centrum (LUMC Leids Universitair Medisch Centrum ).
Voor zijn komst naar het RIVM Rijksinstituut voor Volksgezondheid en Milieu was Jaap van Dissel hoofd van de afdeling Infectieziekten bij het LUMC Leids Universitair Medisch Centrum . Daarnaast was hij hoofdopleider Interne Geneeskunde en voorzitter van het Centrum voor Infectieziekten. Hij wisselde zijn carrière bij het LUMC af met een onderzoeksperiode bij het Duke University Medical Center in Durham en het Cold Spring Harbor Laboratory in de Verenigde Staten.
Van Dissel begeleidde meer dan 25 promovendi en publiceerde meer dan 280 wetenschappelijke publicaties, grotendeels over infectieziekten. Daarnaast schreef hij mee aan ruim 75 opleidingsmodules en boeken over infectieziekten.
Naast zijn baan bij het RIVM werkt Jaap van Dissel één dag per week bij het LUMC, waar hij een polikliniek voor afweerstoornissen leidt en diverse onderzoeksprojecten en promovendi begeleidt.
Dr. Bart. L. Haagmans
Bart Haagmans (1963) is a virologist, working at the Viroscience department of the Erasmus Medical Center in Rotterdam. He studied at Utrecht University and obtained his doctorate from the same university. His interest is the pathogenesis of viral infections, including SARS, MERS and the new coronavirus. The study includes the characterization of viral variants and the serological response generated in the different host species. In addition, the genomes of many other new viruses and their variants have been characterized by complete genome analysis. In recent years, for example, we have characterized the genome of the MERS coronavirus, identified the receptor and contributed to the identification of the dromedary camel as the reservoir species. We have tested a vaccine candidate that reduces the transmission of MERS-CoV by vaccinating dromedary camels. He is currently working on further characterizing the SARS-CoV-2 virus, developing molecular and serological tests and vaccine candidates for this virus.
Hier is de inschrijvingvoor zowel voor de reguliere cursus als de online webinar.
Vanzelfsprekend zal deze 2-daagse doorgang vinden onder voorbehoud van verdere ontwikkelingen m.b.t. de COVID-19 pandemie. Er is er is maximaal plaats voor 80 live deelnemers.